Scientific Program
Friday, September 12, 2025
| 09:00-09:15 |
Congress Opening |
Hall A |
|
Welcome message on behalf of the Congress chairpersons
Bruce Mann, Melbourne, Australia
Henry Gomez Moreno, Lima, Peru
Luis Pinillos, Lima, Peru
Mauricio León Rivera, Lima, Peru |
| 09:15-10:30 |
Session 1: Neoadjuvant therapy |
Hall A |
| Chairpersons |
Henry Gomez Moreno, Lima, Peru
Bruce Mann, Melbourne, Australia |
09:15-09:45
09:15
09:25
09:35 |
Debate: That cT1cN0 HER2+ve should have Neoadjuvant Systemic Therapy (NAST)
Yes: Javier Cortes, Madrid, Spain
No: Richard de Boer, Melbourne, Australia
Discussion |
| 09:45-10:00 |
Didactic: Imaging before and during NAST
Karla Sepulveda, Houston, TX, USA |
10:00-10:30
10:00
10:10
10:20 |
Debate: That endocrine therapy is neoadjuvant treatment of choice for ER+ve/HER2-ve disease
Yes: Antonio Llombart, Valencia, Spain
No: Henry Gomez Moreno, Lima, Peru
Discussion |
| 10:30-11:00 |
Coffee break, poster viewing and exhibition visit |
| 11:00-12:00 |
Session 2: Surgery |
Hall A |
| Chairpersons |
Luis Pinillos, Lima, Peru
|
11:00-11:30
11:00
11:10
11:20 |
Debate: Breast conservation, not mastectomy, should be the standard of care for T2 cancers
Yes: Shelley Potter, Bristol, UK
No: Nereida Esparza-Arias, Mexico City, Mexico
Discussion |
11:30-12:00
11:30
11:40
11:50 |
Debate: Radiation therapy should be given to all women under 70 having breast conservation for invasive cancer
Yes: David Antonio Martínez Pérez, Medellin-Antioquia, Colombia
No: Mauricio León Rivera, Lima, Peru
Discussion |
| 12:00-13:30 |
Session 3: HER2+ve disease |
Hall A |
| Chairpersons |
Adriana Freitas, Santa Catarina, Brazil
Javier Cortes, Madrid, Spain |
12:00-12:35
12:00
12:10
12:20 |
Debate: Do anthracyclines still have a place in the treatment of early stage HER2+ve BC?
Yes: Antonio Llombart, Valencia, Spain
No: Richard de Boer, Melbourne, Australia
Discussion |
12:35-12:55
12:35
12:45
12:55 |
Didactic: Understanding HER2 low disease – how to diagnose/how to treat?
Diagnose: Nirmala Pathmanathan, Sydney, Australia
Treat: Jesus Schwartz, Lima, Peru
Discussion |
13:05-13:40
13:05
13:15
13:25 |
Debate: Axillary radiation is better than surgery after neoadjuvant treatment for node positive disease
Yes: TBA
No: Stuart McIntosh, Belfast, UK
Discussion |
| 13:40-14:40 |
Lunch Symposium:
Lunch will be served to session participants only. |
Hall A |
| Chairperson |
|
|
|
| 13:40-14:40 |
Lunch break, poster viewing and exhibition visit |
| 14:40-15:10 |
Session 4: Case discussions |
Hall A |
| Moderator |
Lia Pamela Rebaza, Lima, Peru |
| Case presenters |
Imager: Rosa Cebrian, Lima, Peru
Medical oncologist: Zaida Morante, Lima, Peru
Surgeon: Yanet Carrasco Rojas, Arequipa, Peru
Radiation oncologist: Joseana Ayala, Lima, Peru
Pathologist: Andrea Gomero, Lima, Peru
|
| 15:10-16:10 |
Session 5: ER+ breast cancer
|
Hall A |
| Chairpersons |
Enrique Bargallo, Mexico City, Mexico
Alastair Thompson, Houston, TX, USA |
15:10-15:40
15:10
15:20
15:30
|
Debate: Endocrine therapy: Which drug to use (tamoxifen or AI) and for how long?
Yes: Gerson Mejia, Cochabamba, Bolivia
No: Silvia Falcon, Lima, Peru
Discussion |
15:40-16:10
15:40
15:50
16:00 |
Debate: Postmenopausal women with clinical T1N0 ER+ breast cancer do not need axillary surgery
Yes: Lia Pamela Rebaza, Lima, Peru
No: Bruce Mann, Melbourne, Australia
Discussion |
| 16:10-16:40 |
Coffee break, poster viewing and exhibition visit |
| 16:40-17:40 |
Session 6: HR+ve Metastatic Breast Cancer (MBC) |
Hall A |
| Chairpersons |
Henry Gomez Moreno, Lima, Peru
Natalia Valdivieso, Lima, Peru |
16:40-17:10
16:40
16:50
17:00 |
Debate: Endocrine therapy should be given as 1st line therapy for ALL patients with ER+ve MBC
Yes: Gerson Mejia, Cochabamba, Bolivia
No: Walter Li, Lima, Peru
Discussion |
17:10-17:40
17:10
17:17
17:24
17:31 |
Didactic: What to do after first progression of ER+ breast cancer on three continents: Change ET, CDK4/6i or SERDS?
Javier Cortes, Madrid, Spain
Richard de Boer, Melbourne, Australia
Natalia Valdivieso,Lima, Peru
Discussion |
| 17:40-19:00 |
Poster Session and Networking Reception |
Saturday, September 13, 2025
| 08:30-09:30 |
Breakfast Industry Symposium
|
Hall A |
|
Light refreshments will be served to session participants only. |
| 09:30-10:30 |
Session 7: Screening |
Hall A |
| Chairpersons |
Silvia Falcon, Lima, Peru
Gerardo Castorena, Mexico City, Mexico |
09:30-10:00
09:30
09:40
09:50 |
Debate: That all countries should invest in population-based mammographic screening
Yes: Karla Sepulveda, Houston, TX, USA
No: Mauricio León Rivera, Lima, Peru
Discussion |
| 10:00-10:30 |
Didactic: Screening methods to cover risk assessment and non-mammographic technologies relevant to Latin America
Karla Sepulveda, Houston, TX, USA |
| 10:30-11:00 |
Coffee break, poster viewing and exhibition visit |
| 11:00-12:30 |
Session 8: Triple negative breast cancer |
Hall A |
| Chairpersons |
Richard De Boer, Melbourne, Australia
Shelley Potter, Bristol, UK
|
11:00-11:30
11:00
11:10
11:20 |
Debate: That all stage 2 TNBC patients should be treated according to the Keynote 522 regimen
Yes: Javier Cortes, Madrid, Spain
No: Henry Gomez Moreno, Lima, Peru
Discussion |
| 11:30-12:00 |
Didactic: TNBC subtypes: How do we use them to help patient outcomes?
Nirmala Pathmanathan, Sydney, Australia |
| 12:00-12:30 |
Session 9: Case Discussions |
Hall A |
| Moderator |
Ronald Limon, Santa Cruz de la Sierra, Bolivia |
| Case presenters |
Imager: Liana Falcon, Lima, Peru
Medical oncologist: Natalia Valdivieso, Lima, Peru
Surgeon: Andy Pantoja, Trujillo, Peru
Radiation oncologist: Alberto Lachos, Lima, Peru
Pathologist: Franco Doimi, Lima, Peru |
| 12:30-13:30 |
Session 10: Reducing the risk |
Hall A |
| Chairpersons |
Karla Sepulveda, Houston, TX, USA |
12:30-13:00
12:30
12:40
12:50 |
Debate: All women under 50 with gene mutations should be offered bilateral mastectomy
Yes: Lia Pamela Rebaza, Lima, Peru
No: Stuart McIntosh, Belfast, UK
Discussion |
13:00-13:30
13:00
13:10
13:20 |
Debate: All women presenting with nodal disease should have radiation therapy after mastectomy
Yes: Oscar Niño De Guzman, Cochabamba, Bolivia
No: Valentina Ovalle, Santiago, Chile
Discussion |
| 13:30-14:30 |
Lunch Symposium:
Lunch will be served to session participants only. |
Hall A |
| Chairperson |
|
|
|
| 13:30-14:30 |
Lunch break, poster viewing and exhibition visit |
| 14:30-16:00 |
Session 11: Adjuvant endocrine therapy |
Hall A |
| Chairpersons |
Nirmala Pathmanathan, Sydney, Australia |
| 14:30-15:10 |
Pitching the test in five minutes: Why this test is “best”? |
| 14:30
14:40
14:50
15:00 |
PAM50: Javier Cortes, Madrid, Spain
Oncotytpe/ODX: Henry Gomez Moreno, Lima, Peru
Mammaprint: TBA
Pathology: Henry Guerra, Lima, Peru |
| 15:10-15:30 |
Didactic: Risk assessment (summary) for ER+ breast cancer
Antonio Llombart, Valencia, Spain |
15:30-16:00
15:30
15:40
15:50 |
Debate: That all young women treated with OFS should be given an aromatase inhibitor
Yes: Alastair Thompson, Houston, TX, USA
No: Richard De Boer, Melbourne, Australia
Discussion |
| 16:00-17:00 |
Session 12: Locoregional management |
Hall A |
| Chairpersons |
Lia Pamela Rebaza, Lima, Peru |
16:00-16:30
16:00
16:10
16:20 |
Debate: That patients with heavy axillary nodal disease pre-NACT should have axillary dissection irrespective of response to NACT
Yes: Enrique Bargallo, Mexico City, Mexico
No: Bruce Mann, Melbourne, Australia
Discussion |
| 16:30-17:00 |
Case discussions: Focusing on Locoregional management |
|
| Moderator |
Mauricio León Rivera, Lima, Peru |
|
| Case presenters |
Medical oncologist: Luis Orrego, Lima, Peru
Imager: Pilar Montenegro, Lima, Peru
Surgeon: Oscar Niño De Guzman, Cochabamba, Bolivia
Radiation oncologist: Juan Manuel Trejo, Lima, Peru
Pathologist: Henry Guerra, Lima, Peru
|
|
| 17:00-17:15 |
Congress closing and Award presentation |
Hall A |
|
Bruce Mann, Melbourne, Australia
Henry Gomez Moreno, Lima, Peru
Luis Pinillos, Lima, Peru
Mauricio León Rivera, Lima, Peru |
- Program is subject to change
